Incyte unveils positive results from Phase 2 ruxolitinib cream study
Category: #health  By Pankaj Singh  Date: 2019-10-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Incyte unveils positive results from Phase 2 ruxolitinib cream study

Vitiligo is a prominent skin diseases prevalent across the world that causes skin color loss. The disease is increasingly being taken as a serious issue by various pharmaceutical firms across the globe, who are continuously working towards finding a better treatment to cure this skin disease.

Incyte Corporation, a US based pharmaceutical firm headquartered in Delaware, reportedly announced the positive 52-week results from the company’s dose-ranging, double-blind and randomized, Phase 2 clinical trial evaluating ruxolitinib cream, an anti-inflammatory, nonsteroidal, JAK inhibitor treatment, in adults with vitiligo.

As announced by the firm earlier, the trial met its primary endpoint, showcasing that significantly more patients who were treated with ruxolitinib over a span of 24 weeks attained an improvement of ≥50% from baseline results in the F-VASI50 (facial vitiligo area severity index) score in comparison with the patients who were treated with a non-medicated cream. 

New results seen at week 52 demonstrate significant improvements in full body repigmentation when treated with ruxolitinib cream, calculated by the patient proportion achieving more than or equal to 50% improvement from the baseline in the total T-VASI50 (vitiligo area severity index), a vital secondary endpoint.     

Additionally, after the 52 week-long therapy with 1.5% ruxolitinib cream administered twice daily, 51% patients obtained a greater than or equal to 75% improvement (F-VASI75) and 58% patients achieved F-VASI50. After approximately 24 weeks, F-VASI75 is the primary measure of outcome of both TRuE-V2 and TRuE-V1 randomized Phase 3 clinical trials that are already under progress.

Group Vice President, Inflammation & Autoimmunity at Incyte, Jim Lee, M.D. stated that the company is very encouraged seeing the new positive data showcased at EADV, which demonstrates significant facial as well as total body repigmentation of the vitiligo lesions in patients who were treated by ruxolitinib cream, and continued enhancements with a treatment of longer duration.

Lee added that as the company seeks to provide a highly-needed option for the patients affected by this life changing disease, it is thrilled that pivotal Phase 3 trials which are evaluating ruxolitinib cream in patients with vitiligo are under progress, with their results predicted to be released in 2021.    

 

 

 

 

 

 

 

 

Source credit : https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-52-week-results-randomized-phase-2



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...